NovoCure's Phase 3 TRIDENT trial misses primary endpoint for earlier TTFields therapy

NovoCure announced topline results from its Phase 3 TRIDENT trial evaluating earlier initiation of Tumor Treating Fields therapy in newly diagnosed glioblastoma, which failed to meet its primary endpoint of demonstrating statistically significant overall survival improvement. The trial showed no new safety signals and durable survival benefits in both arms, but the failure to demonstrate early treatment superiority may impact investor confidence in the company's product expansion strategy.